BioView Presents Promising Results from Their Joint Liquid Biopsy Development Project

Results Presented at the Prestigious AACR International Liquid Biopsy Conference

TEL AVIV, Israel, Dec. 18, 2024 /PRNewswire/ -- BioView Ltd. (TASE: BIOV), a company developing advanced medical imaging systems for cancer cell detection, traded on the Tel Aviv Stock Exchange, today announced the completion of the first stage of its joint project with a partner from the UK. The companies presented results from their collaborative liquid biopsy development effort at the prestigious AACR International Liquid Biopsy Conference.

The two companies are co-developing an innovative liquid biopsy test to detect HER2 genetic amplification and protein expression in circulating tumor cells (CTCs) collected from the blood of metastatic breast cancer (MBC) patients. The kit combines a microfluidic CTC enrichment system together with BioView's advanced AI based automated imaging and analysis technology, offering a practical and safer methodology compared to traditional tissue biopsies for repeated patient examination.

CTCs, cancerous cells released from primary tumors or metastases into the bloodstream, can be analyzed using a simple blood test. This approach enables HER2 status monitoring without the risks and complications associated with tissue biopsies. Additionally, it provides a more comprehensive representation of HER2 expression in both primary and metastatic tumors, unlike tissue biopsies which are confined to specific tumor regions.

Promising Results and Key Insights
The study analyzed blood samples from 43 metastatic breast cancer patients. Notably, three out of five patients initially classified as HER2-negative via tissue biopsy were later identified as HER2-positive using the liquid biopsy test. These findings highlight the test's potential as a complementary tool to tissue biopsies, enabling real-time monitoring of HER2 status changes post-diagnosis and improving treatment decisions.

According to the U.S. National Institutes of Health (NIH), approximately 81% of breast cancer patients are HER2-negative at initial diagnosis. Studies indicate this status may change over time. Liquid biopsy blood tests can enable real-time monitoring of such patients, identifying those who may benefit from targeted HER2 therapies like Herceptin or Enhertu.

Expert Commentary
Dr. Chassidy Johnson, Chief Scientist at BioView, stated:
"The results from our joint development presented at the AACR conference mark a significant milestone. They underscore the analytical power of our test to identify diverse HER2 expressions and its potential to identify patients who could benefit from advanced HER2-targeted therapies."

For more information:
Gilad Mandel
[email protected]

SOURCE BioView Ltd.